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Objectives: heat shock protein (HSP70) has been studied in the ischaemic myocardium and proven to provide protection
against ischaemia. However, HSP70 in ischaemic skeletal muscle in patients with peripheral arterial occlusive disease
(PAOD) has not been reported.
Methods: thirty-four patients with PAOD (Fontaine's criteria: stage II: 15; III: 9 and IV: 10, respectively) and ten non-
PAOD controls were enrolled in the study. Calf muscle samples were taken. HSP70 was quantitated by SDS-PAGE using
ultrasensitive silver staining with reference to a series of standard HSP70, and HSP70 mRNA was estimated using
RT-PCR.
Results: in comparison with the controls [median with range: 24.8 (14.1±35.6) ng in 2.5 mg total protein], HSP70 was
increased significantly in PAOD [stage II: 93.1 (62.7±114.3); stage III: 110.1 (89.7±134.5) and stage IV: 77.4 (67.3±101.1)].
Similar results were obtained with HSP70 mRNA.
Conclusions: HSP70 is increased in the ischaemic skeletal muscle in patients with PAOD, and HSP70 expression is
different with regard to clinical stages, and the upregulation of HSP70 mRNA implies that the expression of HSP70 seems
to be regulated at transcriptional level.
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In response to a variety of stresses, cells produce a
series of proteins, i.e. stress proteins. One family of
these stress proteins is so-called heat shock protein
(HSP), and the most prominent HSP is that with
molecular mass 70 kD (HSP70).1,2 To date, induction
of HSP has been demonstrated in all examined
eukaryotic cells and is considered a universal and
highly conserved characteristic.3 HSP70 has been
proven to play an important role in surviving a
critical stress. In protection against ischaemia,
HSP70 has reportedly an important impact on myo-
cardium.4,5 The induction of HSP70 can not only
reduce injury to ischaemic myocardium but also
improve post-ischaemic myocardial recovery.6±8
Another interesting fact is that the so-called
`` preconditioning'' in which myocardium developsPlease address all correspondence to: Y. Liu, Sport- und Rehabili-
tationsmedizin, UniversitaÈt Ulm, SteinhoÈvelstraûe 9, D-89070 Ulm,
Germany.
1078±5884/02/030269  05 $35.00/0 # 2002 Elsevier Science Ltd. Alresistance against ischaemia can be achieved not
only by pre-ischaemia, but also by pre-hyperthermia.
This may indicate a `` cross-protection'' or `` cross-tol-
erance'' against ischaemia.5,9
There are many factors or stressors which cause the
induction of HSP70 including free radical production,
decreased cellular pH, glycogen depletion.3,10
Although the mechanisms of HSP70 induction are not
completely understood, ischaemia and reperfusion
can both cause HSP70 production.11±13 However,
most of the studies dealt with myocardial ischaemia,
and few studies addressed the issue in skeletal mus-
cles. Recently, we have reported that HSP70 could be
induced in skeletal muscle during physical training14
and that HSP70 expression seemed to be dependent
upon the exercise intensity.15 To our knowledge, there
is no report on HSP70 expression in ischaemic human
skeletal muscle.
This study was designed to investigate whether
HSP70 induction takes place in the skeletal muscle in
patients with PAOD and if any, whether the HSP70
expression is different between clinical stages of
PAOD.l rights reserved.
Fig. 1. An example of a silver-stained SDS-PAGE-gel. Lanes 1, 5, 9
and 13 were loaded with known amount of HSP70 0 ng, 25 ng, 50 ng
and 75 ng, respectively. Lanes 2±4, 6±8 and 10±12 represent proteins
derived from patients with PAOD II, IV and III, respectively. Lanes
14 and 15 for controls.
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Subjects
Forty-four subjects (male 31, female 13), aged 62 (50±
72) years, were studied (Table 1).16 There was no sig-
nificant difference with regard to age, sex, body mass
and smoking history. Diabetes was excluded. The age-
matched controls were the patients from traffic acci-
dents who were operated within two hours and
PAOD excluded by clinical examination and Doppler
ankle pressures. PAOD patients were diagnosed by
clinical examination, Doppler ankle pressure and
arterial angiography. Three patients with PAOD II
and all patients with PAOD III underwent a percutan-
eous transluminal angioplasty (PTA) while those with
PAOD IV got an amputation at the knee level. The
other twelve patients with PAOD II did not untergo
any PTA or vascular surgery procedure. This study
was approved by the ethics committee of the Univer-
sity of Ulm (Ulm, Germany) and informed consent of
all subjects were obtained.
Muscle sampling
From the twelve patients with PAOD II who did not
undergo any PTA or vascular surgery, muscle samples
were obtained by fine needle biopsy.14,15 Muscle sam-
ples from the other subjects were obtained during the
percutaneous transluminal angioplasty or vascular
surgery procedure or operation on trauma (for con-
trols) under sterile conditions (open biopsy). The mus-
cle samples were taken prior to the planned PTA or
surgical procedure. All muscle samples were taken
from the m. gastrocnemius, and in the controls muscle
samples were taken from the not-traumatic side.
About 0.5 g (by open biopsy) or 15 mg (by fine needle
biopsy) muscle tissue was taken and frozen immedi-
ately in liquid nitrogen, and then transfered to ÿ80C
for subsequent analysis.Table 1. Subjects included in the study (median wit
Control PAOD II
Number of subjects 10 15
Age (years) 62 (54±71) 63 (54±68
Body mass (kg) 71 (63±81) 73 (63±85
Clinical
classification
no PAOD Intermitte
claudic
ABI 1.15 (1.02±1.23) 0.82 (0.72
ABI, Ankle±brachial index for systolic blood pressure p5 0.01 in comparison between any two of the grou
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The quantitation of HSP70 was done on sodium do-
decyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) using silver staining with referring to a
series of standard HSP70, the details were described
elsewhere.15 In brief, about 5 mg muscle tissue was
removed from the muscle samples and homogenised
in protein-extraction buffer,17 and total protein con-
centration of the homogenates was determined
according to Lowry et al.18 Total protein measuring
2.5 mg was loaded on SDS-PAGE for the protein sep-
aration.19 HSP70 bands of muscle samples were
detected using ultrasensitive silver staining,20 identi-
fied according to the standard HSP70 run parallel to
the samples (Fig. 1). The certainty of HSP70 bands
detected by silver staining was verified with Western
blot using specific antibody (Clone 2A4, Affinity Bio-
Reagents, Golden, CO, U.S.A.).14h range).
PAOD III PAOD IV
9 10
) 60 (50±70) 63 (55±72)
) 72 (59±86) 73 (64±79)
nt
ation
Resting leg pain PAOD IIInecrotic
changes of the
involved tissues
±0.96) 0.57 (0.50±0.69) 0.38 (0.29±0.55)
.
ps.
RT-PCR
HSP70 in PAOD 271About 5 mg muscle tissue were taken to extract total
RNA using phenol extraction (RNACleanTM System,
AGS Co., Heidelberg, Germany), and total RNA was
dissolved in a final volume of 5 ul for each 1 mg mus-
cle tissue. Oligo (dT) primed synthesis of cDNA was
performed using MuLV reverse transcriptase (Perkin
Elmer, Roche Molecular System, Inc., Branchburg, NJ
U.S.A.) according to the standard protocol of the pro-
vider. Amplification of cDNA for HSP70 was per-
formed according to the method reported by Taggart
et al.21 In brief, the total reaction volume for each
sample was 50 ml containing 25 pmol of each primer,
100 mM of each dNTP, 2 mM MgCl2, and 0.5 unit of Tag
polymerase. Thirty-five cycles of 45 s at 94C, 60 s at
56C, and 30 s at 72C were performed in a micropro-
cessor controlled incubation system (Crocodiel III,
Appligene Co., F-67402 Illkirch, France). Simultan-
eously, PCR amplification for a-actin of skeletal mus-
cle was done according to the method reported by
Peuker & Pette.22 Product of RT-PCR for a-actin
served as an internal reference for HSP70 mRNA.
The expected products of RT-PCR for HSP70 and
a-actin are 200 bp and 367 bp segments, respectively.
The RT-PCR products were densitometricallyLane         1      2    3       4        5
367 bp
200 bp
Fig. 2. An example of RT-PCR products for HSP70 and a-actin.
Lane 3 is the molecular size lane. Lanes 1, 2, 4 and 5 were loaded
with samples from PAOD IV, PAOD III, PAOD II and controls. The
PCR products for HSP70 (200 bp) and a-actin (367 bp) are indicated.measured on 3% agarose-gel containing ethidium
bromide (Fig. 2).
Data analysis
Samples were run in replicate. The calculation of
HSP70 amount followed the linear regression between
densitometric values and known standard HSP70
amounts.14,15 HSP70 mRNA is expressed by its
RT-PCR product in relation to the corresponding
RT-PCR product for a-actin (i.e. ratio of RT-PCR pro-
ducts for HSP70/a-actin). Data are expressed as
median with range, and the difference was tested
with nonparametric methods (the Mann±Whitney
U-test), the difference was assumed to be significant
if p5 0.05.
Results
All samples were successfully analysed. In com-
parison with that of the controls, HSP70 increased
significantly in patients with PAOD II (p5 0.01), and
HSP70 in patients with PAOD III had a further
increase reaching about five-folds that of the controls
(p5 0.01). Interestingly, HSP70 in PAOD IV did not
increase further, but decreased significantly in com-
parison with that of PAOD III (p5 0.01), although it
remained higher than that of the controls (Fig. 3). The
difference of HSP70 levels was statistically significant
between each two groups.
Similarly, RT-PCR results showed that in comparison
with controls, HSP70 mRNA is increased significantly
in patients with PAOD (p5 0.01); (Fig. 4), and reached
the highest level in PAOD III. Again, HSP70 mRNA20
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Fig. 3. HSP70 (ng) was determined in 2.5mg loaded total protein
from skeletal muscle samples (median with range). In comparison
with controls, HSP70 increased in each of stage of PAOD (p5 0.01),
and HSP70 level is different between clinical stages (p5 0.01).
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Fig. 4. HSP70 mRNA is represented by the ratio of HSP70/a-actin
RT-PCR products (median with range), it is significantly increased
in PAOD, and the highest level of HSP70 mRNA was observed in
muscle samples of PAOD III. In comparison with that of PAOD III,
HSP70 mRNA decreased distinctly in PAOD IV though it remained
elevated compared to that of controls.
272 Y. Liu et al.did not increase further but decrease in PAOD IV
compared to that in PAOD III (p5 0.05).
Discussion
Studies dealing with HSP70 in ischaemic skeletal mus-
cle in human have not yet been reported. In the pre-
sent study we have measured HSP70 (both at protein
and mRNA level) in the relevant skeletal muscle and
found that in comparison with the controls, HSP70
increased in the patients with PAOD, and that HSP70
expression differed between clinical stages of the
disease.
This implies that HSP70 induction is associated
with the degree of the disease. We have previously
investigated the distribution of myosin heavy chain
(MHC) isoforms in PAOD patients and found that
with advancing disease the percentage of MHC I
increases.24 HSP70 may be associated with certain
MHC isoforms.25,26 The induction of HSP70 in skeletal
muscle may also be affected by the change of MHC
isoforms in PAOD patients.
The results of HSP70 at the protein level are further
supported by HSP70 mRNA determined by RT-PCR,
which suggests that HSP70 in ischaemic skeletal
muscle is essentially upregulated, and the regula-
tion of HSP70 expression may take place at the
transcriptional level.
Interestingly, the highest level of HSP70 in patients
with PAOD was observed in stage III. Several factors
might be responsible for this unexpected result. First,Eur J Vasc Endovasc Surg Vol 24, September 2002in PAOD IV the substrates as well as energy for meta-
bolism needed may be limited23,27 so that the synthesis
of proteins including HSP70 may be reduced. Against
the result of HSP70 mRNA was the similar to that of
HSP70 at the protein level, indicating that the regula-
tion of HSP70 expression may also take place at tran-
scriptional level. Second, PAOD IV patient may be
unable to exercise, and exercise-induced physiological
and biochemical changes may induce HSP70. Finally,
reperfusion has been reported to have impact on
HSP70 induction, and in PAOD IV reperfusion might
not occur or might not play so important role.
It is generally accepted that HSP70 can confer pro-
tection against critical ischaemia.4,28,29 It would be
important to know whether the ischaemic skeletal
muscle can also be preconditioned by expressing
HSP70 in PAODIV. It is not clear whether the failure
to produce higher HSP70 in PAOD IV might be
responsible for the irreversible tissue damage. Further
studies are required.
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